JP2001151671A - Particle formulation with protrusion - Google Patents
Particle formulation with protrusionInfo
- Publication number
- JP2001151671A JP2001151671A JP2000248258A JP2000248258A JP2001151671A JP 2001151671 A JP2001151671 A JP 2001151671A JP 2000248258 A JP2000248258 A JP 2000248258A JP 2000248258 A JP2000248258 A JP 2000248258A JP 2001151671 A JP2001151671 A JP 2001151671A
- Authority
- JP
- Japan
- Prior art keywords
- particle
- projections
- particle preparation
- projection
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
Abstract
(57)【要約】
【課題】 適度の流動性を保ちながらも転がりにくいと
いう極めて優れた性質を有し、調剤操作性に優れた突起
付き粒子製剤の提供。
【解決手段】 本発明は、円形度係数が0.85〜1.
00の範囲内にある球形粒子に突起が形成されてなる突
起付き粒子製剤であって、該突起の程度が下記式
B=(r2−r1)/r2
式中、r1は突起付き粒子投影像に内接する円の半径を
表わし、r2は突起付き粒子投影像に外接する円の半径
を表わす、で定義される突起度Bの値として0.05〜
0.50の範囲内にあることを特徴とする突起付き粒子
製剤に関する。(57) [Summary] [Problem] To provide a particle preparation with projections having extremely excellent properties of being hard to roll while maintaining appropriate fluidity, and excellent in dispensing operability. SOLUTION: The present invention has a circularity coefficient of 0.85 to 1.
A protrusion-formed particle preparation in which protrusions are formed on spherical particles in the range of 00, wherein the degree of the protrusions is represented by the following formula B = (r 2 −r 1 ) / r 2 , wherein r 1 is a protrusion. Represents a radius of a circle inscribed in the particle projection image, and r 2 represents a radius of a circle circumscribed in the particle projection image with projections.
A particle preparation having protrusions, which is in the range of 0.50.
Description
【0001】[0001]
【発明の属する技術分野】本発明は調剤操作性に優れた
突起付き粒子製剤及びその製造方法に関する。本発明の
突起付き粒子製剤は、適度の流動性を保ちながらも転が
りにくいという極めて優れた性質を有しており、調剤操
作性に優れた粒子製剤として極めて有用である。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a particle preparation with projections having excellent dispensing operability and a method for producing the same. The particle preparation with projections of the present invention has an extremely excellent property that it is difficult to roll while maintaining an appropriate fluidity, and is extremely useful as a particle preparation having excellent dispensing operability.
【0002】[0002]
【従来の技術】医薬品の経口固形製剤において、そのほ
とんどは薬効成分の粉末に種々の添加剤を加えこれを造
粒することによって粒子状物となし、その粒子状物を必
要に応じてさらに加工することにより製造されている。
そのため、造粒技術は製剤加工技術の中でも最も重要な
技術として種々の研究がなされており、生産用造粒装置
等についての改良も種々なされている。2. Description of the Related Art In the case of oral solid pharmaceutical preparations, most of them are formed into particles by adding various additives to a powder of a medicinal ingredient and granulating the powder, and the particles are further processed as required. It is manufactured by doing.
For this reason, various studies have been made on the granulation technology as the most important technology among the formulation processing technologies, and various improvements have been made on a production granulation device and the like.
【0003】現在、生産用造粒装置の中には、粒度分布
のシャープな球状粒子の形成を指向した撹拌混合造粒機
や転動造粒機が開発されており、粒子径が均一で且つ表
面の滑らかな細粒剤や顆粒剤を製造することが可能とな
っている。さらに、苦みの隠蔽、徐放化、腸溶化などを
目的としたコーティング工程においても転動造粒機など
の利用により、円形度の高い粒子製剤を製造することが
可能となっている。At present, among production granulators, agitated mixing granulators and tumbling granulators aiming at forming spherical particles having a sharp particle size distribution have been developed. It has become possible to produce fine granules and granules having a smooth surface. Further, it is possible to produce a particle preparation having a high degree of circularity by using a tumbling granulator also in a coating step for the purpose of masking bitterness, sustained release, entericization, and the like.
【0004】ところで、調剤量の加減が必要な細粒剤や
顆粒剤等の粒子製剤においては、一般に「調剤の操作が
し易いこと(優れた調剤操作性)」が要求されている
が、優れた粒子製剤にとって流動性は最も基本的な物理
特性であり、表面が滑らかな球状粒子はその条件を満た
している。[0004] By the way, in the case of fine particles and granules, which require an adjustment of the amount of preparation, it is generally required that "dispensing operation is easy (excellent dispensing operability)". Fluidity is the most basic physical property for a prepared particle formulation, and spherical particles with a smooth surface meet that requirement.
【0005】しかしながら、調剤操作において障害とな
る諸現象の一つとして、流動性の優れた粒子製剤によく
見られる転逃性の問題が挙げられる。すなわち、粒子製
剤の流動性が余りにも良すぎる場合、秤量や薬包紙への
分割等の調剤操作に際して、粒子製剤が転がりだし所定
の場所から逃避することがあり、そのため粒子製剤の一
部が散逸し使用できなくなってしまうような事態が数多
く見られている。[0005] However, as one of the phenomena obstructing the dispensing operation, there is a problem of run-off property often seen in a particle preparation having excellent fluidity. In other words, if the fluidity of the particle preparation is too good, the particle preparation may roll and escape from a predetermined place during dispensing operations such as weighing and division into medicine packaging paper, so that a part of the particle preparation is dissipated. There are many situations that make it unusable.
【0006】この粒子製剤の転逃性に関して、青木ら
は、粉粒体の取り扱いの難易を表現する尺度としての逃
避性について検討し、その結果、調剤用粒体に適した特
性として粒子の形状が不整形で表面が粗であることが好
ましいことを報告した(薬剤学、27巻、103〜106頁、19
67年)。Aoki et al. Studied the escape property of the particle preparation as a measure for expressing the difficulty of handling the powder, and as a result, as a characteristic suitable for the preparation granule, the shape of the particle was examined. Reported that the surface was preferably irregular and rough (Pharmaceutics, 27, 103-106, 19
67 years).
【0007】また、坂下らは、好ましい粒子製剤とは、
付着性がなく流動性はよいが球形以外の転がりにくい粉
体であると指摘した(最近の製剤技術とその応用 I、
23〜28頁、1984年(株)医薬ジャーナル社発行)。Also, Sakashita et al. Describe a preferred particle preparation
He pointed out that it is a powder that does not adhere and has good fluidity but is hard to roll except for spherical shapes (Recent formulation technology and its applications I,
23-28, 1984 (published by Pharmaceutical Journal Co., Ltd.).
【0008】しかし、適度の流動性を持つがころがりに
くい形状を有する粒子製剤に関して、それが具体的にど
の様な形態の粒子であるのか、またどの様にすればその
粒子製剤を製造できるのかについては全く記載も示唆も
されていない。[0008] However, regarding a particle preparation having an appropriate flowability but a shape that does not easily roll, it is necessary to specifically describe what form the particles are and how to prepare the particle preparation. Is not described or suggested at all.
【0009】一方、流動層造粒や破砕造粒による粒子製
剤の製造過程において、たまたま不定型な粒子しか製造
できないような場合があるが、それは結果として不定型
な粒子が製造されたのに過ぎないのであって、本発明の
ような形状が制御された転がりにくい粒子の製造を可能
にしているわけではない。[0009] On the other hand, in the process of producing a particle preparation by fluidized bed granulation or crushing granulation, there may be cases where only irregular particles can be produced by chance, but only as a result, irregular particles are produced. However, this does not mean that it is possible to produce particles having a controlled shape and hard to roll as in the present invention.
【0010】このように、造粒技術の進歩により真球粒
子の製造については比較的容易になってきたけれども、
表面の滑らかな球状粒子の転逃性から生じる調剤操作上
の問題を解決するような粒子製剤については未だ知られ
ていない。As described above, although the production of true spherical particles has become relatively easy due to the advance of granulation technology,
There is still no known particle preparation which solves the problem of dispensing operation resulting from the escape property of spherical particles having a smooth surface.
【0011】[0011]
【発明が解決しようとする課題】本発明の目的は、適度
の流動性を保ちながらも転がりにくいという極めて優れ
た性質を有する、調剤操作性に優れた粒子製剤を提供す
ることにある。SUMMARY OF THE INVENTION An object of the present invention is to provide a particle preparation excellent in dispensing operability, which has an extremely excellent property that it is difficult to roll while maintaining an appropriate fluidity.
【0012】[0012]
【課題を解決するための手段】本発明者らは、球形粒子
に一定の突起度をもつ突起が形成されてなる突起付き粒
子製剤が、適度の流動性を保ちながらも転がりにくいと
いう調剤操作上きわめて優れた性質を有することを見出
した。Means for Solving the Problems The present inventors have found that a particle preparation with projections, in which projections having a certain degree of projection are formed on spherical particles, is difficult to roll while maintaining appropriate fluidity. It has been found that it has very good properties.
【0013】しかして、本発明によれば、円形度係数が
0.85〜1.00の範囲内にある球形粒子の表面に突
起が形成されてなる突起付き粒子製剤であって、該突起
の程度が下記式 B=(r2−r1)/r2 式中、r1は突起付き粒子投影像に内接する円の半径を
表わし、r2は突起付き粒子投影像に外接する円の半径
を表わす、で定義される突起度Bの値として0.05〜
0.50の範囲内にあることを特徴とする突起付き粒子
製剤が提供される。Thus, according to the present invention, there is provided a particle preparation having projections, wherein projections are formed on the surface of spherical particles having a circularity coefficient in the range of 0.85 to 1.00. The degree is expressed by the following equation: B = (r 2 −r 1 ) / r 2 In the equation, r 1 represents the radius of a circle inscribed in the projected image of the projected particle, and r 2 is the radius of a circle circumscribed in the projected image of the projected particle. Represents a value of the degree of protrusion B defined by 0.05 to
Provided is a particle formulation with protrusions, wherein the formulation is in the range of 0.50.
【0014】また、本発明によれば、球形粒子に結合剤
溶液の噴霧下で突起形成剤を粉末散布し、粒子表面に突
起を形成させることを特徴とする突起付き粒子製剤の製
造方法が提供される。Further, according to the present invention, there is provided a method for producing a particle preparation having projections, wherein a projection-forming agent is sprayed on spherical particles under spraying of a binder solution to form projections on the surface of the particles. Is done.
【0015】更に、本発明によれば、突起形成剤の被覆
により形成される突起層の内層部分及び/又は外層部分
に、さらに溶出制御効果を示す被膜層を有する突起付き
粒子製剤が提供される。Further, according to the present invention, there is provided a particle preparation with projections having a coating layer exhibiting a dissolution controlling effect on an inner layer portion and / or an outer layer portion of a projection layer formed by coating with a projection forming agent. .
【0016】本発明において、球形粒子は、円形度係数
が0.85〜1.00、特に0.90〜1.00の範囲
内にある球形状の粒子であり、該球形粒子は、突起を形
成させるための突起形成剤を被覆させる際の核として用
いられる。この球形粒子は、一般に、薬効成分及び通常
の固形製剤に用いられる賦形剤、例えば、乳糖、白糖、
D-マンニトール等の糖類;バレイショデンプン等のデ
ンプン類;結晶セルロース等のセルロース誘導体;リン
酸水素カルシウム、硫酸カルシウム等の無機塩類等を含
有する。In the present invention, the spherical particle is a spherical particle having a circularity coefficient in the range of 0.85 to 1.00, particularly 0.90 to 1.00. It is used as a nucleus when coating a projection-forming agent to be formed. The spherical particles generally contain active ingredients and excipients used in usual solid preparations, such as lactose, sucrose,
It contains saccharides such as D-mannitol; starches such as potato starch; cellulose derivatives such as crystalline cellulose; and inorganic salts such as calcium hydrogen phosphate and calcium sulfate.
【0017】ここで、円形度係数αは、長さLの曲線に
囲まれた部分の面積をFとするとき、次式に従って算出
される値である。Here, the circularity coefficient α is a value calculated according to the following equation, where F is the area of the portion surrounded by the curve having the length L.
【0018】α=4πF/L2 本発明における円形度係数は、顕微鏡にて拡大した粒子
投影像について周囲長(L)と投影面積(F)を求め、
上記式にあてはめることによって算出することができ
る。Α = 4πF / L 2 The circularity coefficient in the present invention is obtained by calculating the perimeter (L) and the projected area (F) of a particle projection image magnified by a microscope.
It can be calculated by applying the above equation.
【0019】球形粒子に含まれる薬効成分は、球形粒子
中に上記賦形剤と混合された状態で存在していてもよ
く、また、薬効成分を含有しない球形核粒子上に薬効成
分が被覆された状態で存在していてもよい。The medicinal component contained in the spherical particles may be present in the spherical particle in a state of being mixed with the above-mentioned excipient, or the medicinal component may be coated on spherical core particles containing no medicinal component. It may exist in a state where it is not.
【0020】本発明において用いられる球形粒子の大き
さには特に制約はないが、一般に、平均粒子径が2000μ
m以下、特に100−1000μmの範囲内にあるものが好適で
ある。The size of the spherical particles used in the present invention is not particularly limited, but generally, the average particle size is 2000 μm.
m or less, especially in the range of 100-1000 μm.
【0021】これらの球形粒子の製造は、例えば、薬効
成分と前記の如き賦形剤を、必要に応じて、白糖等の糖
類;トウモロコシ、バレイショ等のデンプン類;メチル
セルロース、ヒドロキシプロピルセルロース等のセルロ
ース誘導体;ポリビニルアルコール、ポリビニルピロリ
ドン等のビニル系高分子類;ポリアクリル酸ナトリウ
ム、メタアクリル酸コポリマー等のアクリル系高分子
類;ポリエチレングリコール等の多価アルコール類;
水;エタノール;水−エタノール混液等の結合剤又は結
合剤溶液を添加しながら遠心転動造粒装置を用いて造粒
し、形成される顆粒を乾燥後整粒するか、或いは、薬効
成分を含有しない球形核粒子に、例えば、白糖等の糖
類;トウモロコシ、バレイショ等のデンプン類;メチル
セルロース、ヒドロキシプロピルセルロース等のセルロ
ース誘導体;ポリビニルアルコール、ポリビニルピロリ
ドン等のビニル系高分子類;ポリアクリル酸ナトリウ
ム、メタアクリル酸コポリマー等のアクリル系高分子
類;ポリエチレングリコール等の多価アルコール類等の
結合剤を水、エタノール、水−エタノール混液等に溶解
することにより得られる結合剤溶液を噴霧しながら、粉
末状の薬効成分を散布し、球形核粒子に薬効成分を被覆
させることにより行なうことができる。For the production of these spherical particles, for example, a medicinal ingredient and the above-mentioned excipients are added, if necessary, to sugars such as sucrose; starches such as corn and potato; cellulose such as methylcellulose and hydroxypropylcellulose. Derivatives; vinyl polymers such as polyvinyl alcohol and polyvinyl pyrrolidone; acrylic polymers such as sodium polyacrylate and methacrylic acid copolymer; polyhydric alcohols such as polyethylene glycol;
Water; ethanol; granulation using a centrifugal tumbling granulator while adding a binder or a binder solution such as a water-ethanol mixture, and drying the resulting granules, or sizing the medicinal ingredients. The spherical core particles not containing, for example, sugars such as sucrose; starches such as corn and potato; cellulose derivatives such as methylcellulose and hydroxypropylcellulose; vinyl polymers such as polyvinyl alcohol and polyvinylpyrrolidone; sodium polyacrylate; While spraying a binder solution obtained by dissolving a binder such as an acrylic polymer such as a methacrylic acid copolymer or a polyhydric alcohol such as polyethylene glycol in water, ethanol, or a water-ethanol mixture, By spraying a medicinal component in the form of a sphere and coating the spherical core particles with the medicinal component Door can be.
【0022】なお、上記球形粒子の製造において用いる
ことのできる球形核粒子は市販もされており、例えばノ
ンパレル(フロイント産業 製、精製白糖又は精製白糖
とデンプンからなる白色の球形顆粒)やセルフィア(旭
化成工業 製、結晶セルロースからなる白色ないし帯黄
白色の球形顆粒)等を挙げることができる。これら市販
の球形核粒子を用いる場合、一般に、1000μm以下、好
ましくは150-850μmの平均粒子径を持つものが好適に利
用され、それらの球形核粒子の安息角は一般に約25〜
35度程度の値を示し、それらの転逃率は一般に約50
〜70%程度の値を示す。このような値の安息角と転逃
率をもつ球形核粒子であればいずれのものでも使用可能
である。Spherical core particles which can be used in the production of the above-mentioned spherical particles are also commercially available, for example, nonpareil (made by Freund Corporation, white spherical granules comprising purified sucrose or purified sucrose and starch) and Selfia (Asahi Kasei) Industrial, white or yellowish white spherical granules composed of crystalline cellulose). When using these commercially available spherical core particles, generally, those having an average particle size of 1000 μm or less, preferably 150 to 850 μm are suitably used, and the angle of repose of those spherical core particles is generally about 25 to
It shows a value of about 35 degrees and their escape rate is generally about 50
A value of about 70% is shown. Any spherical core particle having such values of the angle of repose and the escape rate can be used.
【0023】なお、本発明において、「安息角」は、日
高重助:粉体工学会誌、24巻、664〜669頁、1
987年に記載された「注入法」により測定された値で
あり、また、「転逃率」は、青木大:薬剤学、27巻、
103〜106頁、1967年に記載された方法(後記
実施例3参照)によって測定された値である。In the present invention, the "angle of repose" is defined as "Hidaka Shigesuke", Journal of the Society of Powder Technology, Vol. 24, pp. 664-669, 1
The values measured by the “injection method” described in 987, and the “escape rate” are shown in Aoki University: Pharmaceutical Sciences, Vol. 27,
It is a value measured by the method described in pages 103 to 106, 1967 (see Example 3 described later).
【0024】本発明において使用される突起形成剤に
は、球形粒子にそれを被覆造粒させることにより粒子表
面に突起を形成させることができるような粉末状の賦形
剤が包含される。かかる粉末状の賦形剤としては、平均
粒子径10μm以下の微粉末状の物質、例えば、酸化チ
タン、合成ケイ酸アルミニウム、乾燥水酸化アルミニウ
ムゲル、ステアリン酸マグネシウム、ケイ酸カルシウ
ム、精製白糖等から選ばれる少なくとも1種の化合物が
挙げられ、好ましくは酸化チタン、合成ケイ酸アルミニ
ウム又は乾燥水酸化アルミニウムゲルを用いることがで
きる。The projection-forming agent used in the present invention includes excipients in the form of powder that can form projections on the surface of spherical particles by coating and granulating the spherical particles. Examples of such powdered excipients include fine powdered substances having an average particle size of 10 μm or less, such as titanium oxide, synthetic aluminum silicate, dried aluminum hydroxide gel, magnesium stearate, calcium silicate, purified sucrose, and the like. At least one compound selected is mentioned, and preferably, titanium oxide, synthetic aluminum silicate or dried aluminum hydroxide gel can be used.
【0025】本発明の突起形成剤の前記球状粒子への被
覆造粒は、例えば、球形粒子に結合剤溶液を噴霧しなが
ら突起形成剤を粉末散布することにより行なうことがで
きる。The granulation of the spherical particles with the projection-forming agent of the present invention can be carried out, for example, by spraying a powder of the projection-forming agent while spraying a binder solution on the spherical particles.
【0026】上記被覆造粒工程において用いられる結合
剤溶液としては、例えば、精製白糖、ヒドロキシプロピ
ルセルロース、ヒドロキシプロピルメチルセルロース、
メチルセルロース、エチルセルロース等の結合剤を水、
エタノール、水−エタノール混液等に溶解したものが挙
げられ、該溶液は、一般に0.1〜70%(W/W)、
好ましくは0.5〜50%(W/W)程度の濃度の溶液
として用いることができる。Examples of the binder solution used in the coating granulation step include purified sucrose, hydroxypropylcellulose, hydroxypropylmethylcellulose,
Methyl cellulose, ethyl cellulose and other binders with water,
Examples thereof include those dissolved in ethanol, a mixed solution of water and ethanol, and the solution is generally 0.1 to 70% (W / W);
Preferably, it can be used as a solution having a concentration of about 0.5 to 50% (W / W).
【0027】被覆造粒工程に用いられる造粒装置は、通
常の造粒装置であればいずれも使用が可能であるが、特
に遠心転動造粒装置を有利に使用することができる。As the granulating apparatus used in the coating granulation step, any conventional granulating apparatus can be used, and particularly, a centrifugal tumbling granulator can be advantageously used.
【0028】例えば、遠心転動造粒装置を用いる場合、
フロイント産業 製の遠心流動型コーティング造粒装置
のような、円筒形の缶体の底部に平滑な表面を有する回
転円盤を備え、この回転円盤の縁と缶体との隙間から空
気を送って粉粒体の落下を防止するとともに粉粒体の流
動化、混合および乾燥を行い、回転円盤の上方に噴霧装
置を設けた構造からなる装置を用いることが好ましい。
しかし、遠心流動型コーティング造粒装置と同様の機能
を有するものであれば、この遠心転動造粒装置に特に限
定されるものではない。遠心転動造粒装置における回転
円盤の回転数は、一般に20〜400RPM、好ましくは
50〜300RPMの範囲内が適当であり、回転円盤の縁
と缶体との隙間から送られる空気温度は、一般に10〜
80℃、好ましくは20〜60℃程度の温度を挙げるこ
とができる。結合剤溶液を噴霧するための噴霧装置につ
いても、通常の製剤工程において溶液の噴霧のために用
いられている加圧ノズル、回転円盤、二流体ノズル等を
使用することができるが、本発明においては二流体スプ
レーガンが好適に使用できる。For example, when using a centrifugal rolling granulator,
A rotating disk having a smooth surface is provided at the bottom of a cylindrical can, such as a centrifugal flow type coating granulator manufactured by Freund Corporation, and air is sent from the gap between the edge of the rotating disk and the can to powder. It is preferable to use an apparatus having a structure in which the granules are prevented from falling, fluidized, mixed and dried, and a spray device is provided above the rotating disk.
However, the centrifugal tumbling granulator is not particularly limited as long as it has the same function as the centrifugal flow type coating granulator. The rotation speed of the rotating disk in the centrifugal rolling granulator is generally in the range of 20 to 400 RPM, preferably 50 to 300 RPM, and the temperature of air sent from the gap between the edge of the rotating disk and the can body is generally 10
A temperature of 80 ° C, preferably about 20 to 60 ° C can be mentioned. As for the spraying device for spraying the binder solution, a pressurizing nozzle, a rotating disk, a two-fluid nozzle and the like which are used for spraying the solution in a normal preparation process can be used. Preferably, a two-fluid spray gun can be used.
【0029】球形粒子に対する結合剤溶液の使用割合は
特に制限はないが、一般に球形粒子1g当たり結合剤溶
液を0.3〜3g、好ましくは0.5〜2gの範囲内で
用いることができ、また、突起形成剤の使用割合につい
ては一般に球形粒子1g当たり突起形成剤を0.1〜4
g、好ましくは0.3〜3gの範囲内で用いることがで
きる。The ratio of the binder solution to the spherical particles is not particularly limited, but generally the binder solution can be used in an amount of 0.3 to 3 g, preferably 0.5 to 2 g per 1 g of the spherical particles. In addition, the proportion of the protrusion forming agent used is generally 0.1 to 4 per g of the spherical particles.
g, preferably in the range of 0.3 to 3 g.
【0030】この突起形成剤の被覆造粒により球状粒子
の粒子表面に突起が形成される。形成される突起の程度
は、本発明においては、下記式の突起度(B)の値によ
って表わすことができる。The projections are formed on the particle surfaces of the spherical particles by the coating granulation of the projection forming agent. In the present invention, the degree of the formed protrusion can be represented by the value of the protrusion degree (B) in the following equation.
【0031】B=(r2−r1)/r2 式中、Bは突起度を表わし、r1は突起付き粒子投影像
に内接する円の半径を表わし,r2は突起付き粒子投影
像に外接する円の半径を表わす。B = (r 2 −r 1 ) / r 2 In the formula, B represents the degree of protrusion, r 1 represents the radius of a circle inscribed in the projected particle projected image, and r 2 represents the projected particle projected image. Represents the radius of a circle circumscribing.
【0032】本発明によれば、本発明の突起付き粒子製
剤は、この突起度(B)が一般に0.05〜0.50の
範囲内にあり、好ましくは0.10〜0.35の範囲内
の値を有しており且つその標準偏差は通常0.05以下
である。According to the present invention, the particle preparation with protrusions of the present invention has a degree of protrusion (B) generally in the range of 0.05 to 0.50, preferably in the range of 0.10 to 0.35. And the standard deviation is usually 0.05 or less.
【0033】なお、突起度の測定は、通常、顕微鏡にて
拡大した粒子投影像について内接円半径と外接円半径を
求め、上記式にあてはめて算出することができる。The measurement of the degree of protrusion can be usually performed by calculating the inscribed circle radius and the circumscribed circle radius with respect to the particle projection image enlarged by a microscope and applying the above formula.
【0034】球形粒子に突起が形成された結果、本発明
の突起付き粒子製剤の円形度係数は一般に0.60〜
0.90の範囲内の値を示し且つその標準偏差は好まし
くは0.05以下である。As a result of the formation of the projections on the spherical particles, the circularity coefficient of the particle preparation with projections of the present invention is generally 0.60 to 0.60.
It shows a value in the range of 0.90 and its standard deviation is preferably less than 0.05.
【0035】また、このような突起が形成された結果、
本発明の突起付き粒子製剤における安息角の増加及び転
逃率の減少がもたらされる。Further, as a result of the formation of such projections,
This results in an increase in the angle of repose and a decrease in the escape rate in the protruding particle preparation of the present invention.
【0036】本発明において、原料として安息角が約2
5〜35度である球形粒子を使用する場合、それに突起
層を形成させた突起付き粒子製剤は安息角が少なくとも
5度以上増加し、また転逃率が約50〜70%である球
形粒子を使用する場合、突起層の形成による転逃率の減
少は少なくとも10%以上となる。これにより、本発明
の突起付き粒子製剤は、適度の流動性を保ちながらも転
がりにくいという調剤操作上きわめて優れた性質を示
す。In the present invention, the material has a repose angle of about 2
When spherical particles having a diameter of 5 to 35 degrees are used, the particle preparation with projections on which a projection layer is formed increases spherical particles having a repose angle of at least 5 degrees or more and an escape rate of about 50 to 70%. When used, the reduction in the escape rate due to the formation of the projection layer is at least 10% or more. As a result, the particle preparation with protrusions of the present invention exhibits extremely excellent properties in dispensing operation such that it is difficult to roll while maintaining appropriate fluidity.
【0037】かくして得られる本発明の突起付き粒子製
剤は、その使用目的等に応じて、さらに、突起層の内層
部分及び/又は外層部分に、易溶性、胃溶性、腸溶性あ
るいは徐放性等の溶出制御効果を示す被膜層を施すこと
ができる。The thus-obtained particle preparation with projections of the present invention may further contain, for example, easily soluble, gastric, enteric or sustained-release compounds in the inner layer and / or outer layer of the projecting layer, depending on the intended use. Can be applied.
【0038】突起層の内層部分に被膜層を有する本発明
の粒状製剤は、通常、薬効成分を含有する球形粒子に遠
心転動造粒装置、流動層造粒装置等の一般的なコーティ
ング装置を用いて溶出制御効果を示す被膜形成成分をコ
ーティングし、しかる後に突起形成剤を被覆造粒するこ
とにより製造することができる。The granular preparation of the present invention having a coating layer on the inner layer portion of the protruding layer is usually prepared by applying a general coating apparatus such as a centrifugal rolling granulator or a fluidized bed granulator to spherical particles containing a medicinal ingredient. It can be produced by coating a film-forming component exhibiting a dissolution controlling effect by using the composition and then coating and granulating a projection-forming agent.
【0039】また、突起層の外層部分に被膜層を有する
本発明の粒状製剤は、通常、球形粒子に突起形成剤を被
覆造粒することにより得られる突起付き粒子製剤に、上
記のコーティング装置を用いて被膜形成成分をコーティ
ングすることにより製造することができる。The granular preparation of the present invention having a coating layer on the outer layer portion of the projection layer is usually prepared by coating the above-mentioned coating apparatus on a particle preparation with projections obtained by coating and granulating spherical particles with a projection-forming agent. It can be manufactured by coating the film-forming component with the use.
【0040】かかる被膜形成成分において、易溶性又は
胃溶性の被膜形成成分としては、例えば、ヒドロキシプ
ロピルメチルセルロース、ヒドロキシプロピルセルロー
ス、メチルセルロース、ポリビニルアセタールジエチル
アミノアセテート等を挙げることができる。また、腸溶
性の被膜形成成分としては、例えば、セルロースアセテ
ートフタレート、ヒドロキシプロピルメチルセルロース
フタレート、ヒドロキシプロピルメチルセルロースアセ
テートサクシネート、アクリル酸系共重合物(オイドラ
ギット、ローム社製、西ドイツ)等が挙げられ、徐放性
の被膜形成成分としては、例えば、エチルセルロース、
アミノアルキルメタアクリレートコポリマー、ワックス
類等が挙げられる。In such a film-forming component, examples of the easily soluble or gastric-soluble film-forming component include hydroxypropylmethylcellulose, hydroxypropylcellulose, methylcellulose, polyvinyl acetal diethylaminoacetate and the like. Examples of the enteric film-forming component include cellulose acetate phthalate, hydroxypropylmethylcellulose phthalate, hydroxypropylmethylcellulose acetate succinate, and acrylic copolymers (Eudragit, manufactured by Rohm, West Germany). As the release film forming component, for example, ethyl cellulose,
Examples include aminoalkyl methacrylate copolymers and waxes.
【0041】かくして得られる突起付き粒子製剤は、造
粒終了後、例えば、流動層造粒乾燥機、棚段乾燥機等の
乾燥装置を用いて乾燥工程に付し、乾燥終了後必要に応
じて篩過することにより最終製品とすることができる。After the completion of granulation, the thus-obtained particle preparation with protrusions is subjected to a drying step using a drying apparatus such as a fluidized-bed granulator and a tray dryer. The final product can be obtained by sieving.
【0042】以下、実施例により本発明を更に具体的に
説明する。Hereinafter, the present invention will be described more specifically with reference to examples.
【0043】[0043]
【実施例】実施例1 市販のノンパレル103(粒径:24−32(710−
500μm))1000gを遠心流動型コーティング造
粒装置に入れ、ローター回転数を130−160RP
M、スリット空気温度80℃でヒドロキシプロピルセル
ロース水溶液(HPC−L)(2%(W/W))を5−
10mL/分で噴霧しながら、酸化チタンを15g/分
で20分間散布した後、60℃で6時間乾燥した。この突
起付き顆粒の安息角は39度であり、被覆造粒前のノン
パレル103の安息角29度から10度の増加が認めら
れた。EXAMPLE 1 Commercially available nonpareil 103 (particle size: 24-32 (710-
500 μm)) 1000 g was put into a centrifugal flow type coating granulator, and the rotor rotation speed was 130-160 RP.
M, an aqueous solution of hydroxypropylcellulose (HPC-L) (2% (W / W))
While spraying at 10 mL / min, titanium oxide was sprayed at 15 g / min for 20 minutes, and then dried at 60 ° C for 6 hours. The angle of repose of the granules with protrusions was 39 degrees, and an increase of 10 degrees from the angle of repose of 29 degrees of the nonpareil 103 before coating granulation was recognized.
【0044】実施例2 市販のノンパレル101(粒径:32−42(500−
355μm)、円形度係数:0.91±0.01)20
00gを遠心流動型コーティング造粒装置に入れ、ロー
ター回転数を150RPM、スリット空気温度20℃で
下記組成の結合剤溶液を5−37.5mL/分で噴霧し
ながら、アセトアミノフェンを12g/分で33分間散
布した後、60℃で6時間乾燥した。 [結合剤溶液] エチルセルロース 11g 無水エタノ−ル 520g 精製水 3g 得られた顆粒のうち780gを遠心流動型コーティング
造粒装置に入れ、ローター回転数を140−160RP
M、スリット空気温度50℃でヒドロキシプロピルセル
ロース水溶液(HPC−M)(2%(W/W))を7.
5mL/分で噴霧しながら、酸化チタンを8g/分で6
8分間散布した後、40℃で12時間乾燥した。この突
起付き顆粒の安息角は39度であり、被覆造粒前のノン
パレル101の安息角28度から11度の増加が認めら
れた。Example 2 Commercially available nonpareil 101 (particle size: 32-42 (500-
355 μm), circularity coefficient: 0.91 ± 0.01) 20
00 g was placed in a centrifugal fluidized-type coating granulator, and acetaminophen was sprayed at 12 g / min while spraying a binder solution having the following composition at a rotor rotation speed of 150 RPM and a slit air temperature of 20 ° C. at 5-37.5 mL / min. And then dried at 60 ° C. for 6 hours. [Binder solution] Ethyl cellulose 11 g 520 g of anhydrous ethanol 3 g of purified water 780 g of the obtained granules were put into a centrifugal flow type coating granulator, and the rotor rotation speed was 140-160 RP.
M, an aqueous solution of hydroxypropylcellulose (HPC-M) (2% (W / W)) at a slit air temperature of 50 ° C.
While spraying at 5 mL / min, titanium oxide was sprayed at 8 g / min at 6 g / min.
After spraying for 8 minutes, it was dried at 40 ° C. for 12 hours. The angle of repose of the granules with protrusions was 39 degrees, and an increase of 11 degrees from the angle of repose of 28 degrees of the nonpareil 101 before coating granulation was recognized.
【0045】実施例3 市販のノンパレル101(粒径:32−42(500−
355μm)、円形度係数:0.91±0.01)60
0gを遠心流動型コーティング造粒装置に入れ、ロータ
ー回転数を130−150RPM、スリット空気温度2
0℃で下記組成の結合剤溶液を5−20mL/分で噴霧
しながら、アセトアミノフェンを8g/分で26分間散
布した後、60℃で6時間乾燥した。 [結合剤溶液] エチルセルロース 7g 無水エタノ−ル 332g 精製水 2g 得られた顆粒のうち714gを流動層造粒装置に入れ、
吸気温度20−40℃で下記組成の徐放性被膜形成成分
を9mL/分で噴霧し徐放性顆粒を得た。 [徐放性被膜形成成分] エチルセルロース 40g グリセリン脂肪酸エステル 4g 無水エタノ−ル 1215g 精製水 6g ジクロルメタン 725g 得られた顆粒のうち646gを遠心流動型コーティング
造粒装置に入れ、ローター回転数を130−140RP
M、スリット空気温度50℃でヒドロキシプロピルセル
ロース水溶液(HPC−M)(2%(W/W))を7.
5mL/分で噴霧しながら、酸化チタンを8g/分で1
20分間散布した後、60℃で12時間乾燥し徐放性突
起付き顆粒を得た(図1参照)。この徐放性突起付き顆
粒の突起度は0.25±0.04であり、円形度係数は
0.72±0.04であった。また、徐放性突起付き顆
粒の安息角は37度であり、被覆造粒前のノンパレル1
01の安息角28度から9度の増加が認められた。更
に、この顆粒の転逃率は46%であり、被覆造粒前のノ
ンパレル101の転逃率65%から19%の減少が認め
られた。Example 3 Commercially available nonpareil 101 (particle size: 32-42 (500-
355 μm), circularity coefficient: 0.91 ± 0.01) 60
0 g was placed in a centrifugal flow type coating granulator, the rotor rotation speed was 130-150 RPM, and the slit air temperature was 2
Acetaminophen was sprayed at 8 g / min for 26 minutes while spraying a binder solution having the following composition at 0 ° C at 5 to 20 mL / min, and then dried at 60 ° C for 6 hours. [Binder solution] 7 g of ethyl cellulose 332 g of anhydrous ethanol 2 g of purified water 714 g of the obtained granules were put into a fluidized bed granulator,
At an intake temperature of 20 to 40 ° C., a sustained-release film-forming component having the following composition was sprayed at 9 mL / min to obtain sustained-release granules. [Slow release film-forming component] 40 g of ethyl cellulose 4 g of glycerin fatty acid ester 1215 g of anhydrous ethanol 625 g of purified water 725 g of the obtained granules 646 g of the obtained granules were put into a centrifugal flow type coating granulator, and the rotor rotation speed was 130-140 RP.
M, an aqueous solution of hydroxypropylcellulose (HPC-M) (2% (W / W)) at a slit air temperature of 50 ° C.
While spraying at 5 mL / min, the titanium oxide was added at 8 g / min at 1 g / min.
After spraying for 20 minutes, it was dried at 60 ° C. for 12 hours to obtain granules with sustained release projections (see FIG. 1). The degree of protrusion of the granules with sustained release protrusion was 0.25 ± 0.04, and the circularity coefficient was 0.72 ± 0.04. In addition, the angle of repose of the granules with sustained release projections is 37 degrees,
The angle of repose of 01 increased from 28 degrees to 9 degrees. Further, the transfer rate of the granules was 46%, and the transfer rate of the non-pareil 101 before coated granulation was reduced from 65% to 19%.
【0046】なお、転逃率の測定は次のような方法で行
った。すなわち、金属製の円筒に試料2gを充填し、円
筒下部の蓋を急速に開いて15cm下に設置した直径8
cmの金属製円盤中央に落下させ、円盤上に残った試料
の重量を測定し、以下の式から転逃率を算出した。Incidentally, the measurement of the slippage rate was performed by the following method. That is, a metal cylinder was filled with 2 g of the sample, the lid at the bottom of the cylinder was quickly opened, and the diameter of the cylinder was set at 15 cm below.
cm of a metal disk, the weight of the sample remaining on the disk was measured, and the slippage rate was calculated from the following equation.
【0047】転逃率(%)=(a−b)/a×100 a:試料の重量(2.00g) b:円盤上に残った試料の重量 実施例4 市販のセルフィアCP−203(粒径:300−150
μm、円形度係数:0.96±0.01)2400gを
遠心流動型コーティング造粒装置に入れ、ローター回転
数を150RPM、スリット空気温度30℃で下記組成
の結合剤溶液を15−25mL/分で噴霧しながら、塩
酸ロキサチジンアセタートを9.5g/分で54分間散
布した後、40℃で6時間乾燥した。 [結合剤溶液] エチルセルロース 10g 無水エタノ−ル 1008g 精製水 5g 得られた細粒のうち500gを流動層造粒装置に入れ、
吸気温度20−25℃で下記組成の徐放性被膜形成成分
を9mL/分で噴霧し徐放性細粒を得た。 [徐放性被膜形成成分] エチルセルロース 15g グリセリン脂肪酸エステル 2g 無水エタノ−ル 926g 精製水 5g ジクロルメタン 552g 上記の操作を繰り返し、得られた徐放性細粒のうち98
4gを遠心流動型コーティング造粒装置に入れ、ロータ
ー回転数を160RPM、スリット空気温度50−60
℃でヒドロキシプロピルセルロース水溶液(HPC−
M)(2%(W/W))を5−10mL/分で噴霧しな
がら、酸化チタンを10g/分で126分間散布した
後、40℃で8時間乾燥した。この徐放性突起付き細粒
の突起度は0.25±0.02であり、円形度係数は
0.82±0.03であった。また、この徐放性突起付
き細粒の安息角は40度であり、被覆造粒前のセルフィ
アCP−203の安息角34度から6度の増加が認めら
れた。更に、この細粒の転逃率は41%であり、被覆造
粒前のセルフィアCP−203の転逃率52%から11
%の減少が認められた。Overturning rate (%) = (ab) / a × 100 a: Weight of sample (2.00 g) b: Weight of sample remaining on disk Example 4 Commercially available Selfia CP-203 (particle size : 300-150
μm, circularity coefficient: 0.96 ± 0.01) 2400 g was put into a centrifugal flow type coating granulator, the rotor solution was rotated at 150 RPM, the slit air temperature was 30 ° C., and the binder solution having the following composition was 15 to 25 mL / min. After spraying with roxatidine acetate hydrochloride at 9.5 g / min for 54 minutes, the mixture was dried at 40 ° C. for 6 hours. [Binder solution] ethyl cellulose 10 g anhydrous ethanol 1008 g purified water 5 g 500 g of the obtained fine granules was put into a fluidized bed granulator,
At an intake air temperature of 20 to 25 ° C., a sustained release film forming component having the following composition was sprayed at 9 mL / min to obtain sustained release fine granules. [Slow release film forming component] Ethyl cellulose 15 g Glycerin fatty acid ester 2 g Absolute ethanol 926 g Purified water 5 g Dichloromethane 552 g Repeated the above operation, 98 of the sustained release fine particles obtained
4 g was put into a centrifugal flow type coating granulator, the rotor rotation speed was 160 RPM, and the slit air temperature was 50-60.
Aqueous solution of hydroxypropylcellulose (HPC-
M) (2% (W / W)) while spraying titanium oxide at 10 g / min for 126 minutes while spraying at 5-10 mL / min, followed by drying at 40 ° C. for 8 hours. The degree of projection of the fine particles with sustained release projections was 0.25 ± 0.02, and the circularity coefficient was 0.82 ± 0.03. In addition, the angle of repose of the fine particles with sustained release projections was 40 degrees, and an increase of 6 degrees from the angle of repose of Selfia CP-203 before coating granulation of 34 degrees was observed. Further, the sliding rate of the fine granules was 41%, and the sliding rate of Selfia CP-203 before coating granulation was 52% to 11%.
% Decrease was observed.
【図1】実施例3で得られた突起付き顆粒の顕微鏡写真
(倍率100倍)である。FIG. 1 is a micrograph (magnification: 100 ×) of a granule with protrusions obtained in Example 3.
Claims (12)
内にある球形粒子の表面に突起が形成されてなる突起付
き粒子製剤であって、該突起の程度が下記式 B=(r2−r1)/r2 式中、r1は突起付き粒子投影像に内接する円の半径を
表わし、r2は突起付き粒子投影像に外接する円の半径
を表わす、で定義される突起度Bの値として0.05〜
0.50の範囲内にあることを特徴とする突起付き粒子
製剤。1. A particle preparation with projections, wherein projections are formed on the surface of spherical particles having a circularity coefficient in the range of 0.85 to 1.00, wherein the degree of the projections is represented by the following formula B = ( r 2 −r 1 ) / r 2 In the formula, r 1 represents the radius of a circle inscribed in the projected particle projected image, and r 2 represents the radius of a circle circumscribed in the projected particle projected image. The value of the degree of protrusion B is 0.05 to
A particle preparation with projections, which is in the range of 0.50.
内にあり且つその標準偏差が0.05以下である請求項
1記載の突起付き粒子製剤。2. The particle preparation with projections according to claim 1, wherein the circularity coefficient is in the range of 0.60 to 0.90 and the standard deviation thereof is 0.05 or less.
囲内にあり且つその標準偏差が0.05以下である請求
項1記載の突起付き粒子製剤。3. The particle preparation with protrusions according to claim 1, wherein the value of the degree of protrusion B is in the range of 0.10 to 0.35 and the standard deviation thereof is 0.05 or less.
とにより粒子表面に突起を形成させたものである請求項
1〜3のいずれかに記載の突起付き粒子製剤。4. The particle preparation with projections according to claim 1, wherein the projections are formed on the surface of the spherical particles by coating and granulating the particle with a projection forming agent.
核粒子に薬効成分が被覆された構造からなる請求項1〜
4のいずれかに記載の突起付き粒子製剤。5. The spherical particle according to claim 1, wherein the spherical core particle containing no medicinal component is coated with the medicinal component.
4. The particle preparation with projections according to any one of 4.
及び転逃率の減少を生じさせるようなものである請求項
1〜5のいずれかに記載の突起付き粒子製剤。6. The particle preparation with projections according to claim 1, wherein the projections cause an increase in the angle of repose and a decrease in the escape rate in the particle preparation.
る請求項6記載の突起付き粒子製剤。7. The projection-formed particle preparation according to claim 6, wherein the increase in the angle of repose is at least 5 degrees or more.
ある請求項6記載の突起付き粒子製剤。8. The particle preparation with protrusions according to claim 6, wherein the decrease in the rolling rate is at least 10% or more.
末状の物質である請求項4記載の突起付き粒子製剤。9. The preparation according to claim 4, wherein the projection-forming agent is a fine powdery substance having a particle diameter of 10 μm or less.
イ酸アルミニウム又は乾燥水酸化アルミニウムゲルであ
る請求項9記載の突起付き粒子製剤。10. The particle preparation with protrusions according to claim 9, wherein the fine powdery substance is titanium oxide, synthetic aluminum silicate or dried aluminum hydroxide gel.
剤の被覆により形成される突起層の内層部分及び/又は
外層部分に溶出制御効果を示す被膜層を有する請求項4
〜10のいずれかに記載の突起付き粒子製剤。11. The projection-formed particle preparation further comprises a coating layer exhibiting a dissolution controlling effect on an inner layer portion and / or an outer layer portion of the projection layer formed by coating the projection forming agent.
The particle preparation with protrusions according to any one of claims 10 to 10.
起形成剤の粉末を散布し、粒子表面に突起を形成させる
ことを特徴とする突起付き粒子製剤の製造方法。12. A method for producing a particle preparation having projections, wherein a powder of a projection-forming agent is sprayed onto spherical particles under spraying of a binder solution to form projections on the surface of the particles.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2000248258A JP2001151671A (en) | 1999-09-06 | 2000-08-18 | Particle formulation with protrusion |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP11-251439 | 1999-09-06 | ||
| JP25143999 | 1999-09-06 | ||
| JP2000248258A JP2001151671A (en) | 1999-09-06 | 2000-08-18 | Particle formulation with protrusion |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2001151671A true JP2001151671A (en) | 2001-06-05 |
Family
ID=26540197
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000248258A Pending JP2001151671A (en) | 1999-09-06 | 2000-08-18 | Particle formulation with protrusion |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2001151671A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6699584B2 (en) * | 2000-12-14 | 2004-03-02 | Otsuka Chemical Co., Ltd. | Nitric acid-based salt granule and aggregate thereof |
| JP2014080424A (en) * | 2002-12-10 | 2014-05-08 | Cps Orocel Llc | Method of preparing biologically active formulations |
| WO2021002411A1 (en) * | 2019-07-04 | 2021-01-07 | 沢井製薬株式会社 | Method for manufacturing orally disintegrating tablet, and orally disintegrating tablet |
| JP2021181434A (en) * | 2020-05-14 | 2021-11-25 | 沢井製薬株式会社 | Water-insoluble polymer-coated granules, formulations containing them and methods for manufacturing them |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH02174931A (en) * | 1988-09-27 | 1990-07-06 | Takeda Chem Ind Ltd | Nucleate granule and its preparation |
| WO1997039752A1 (en) * | 1996-04-24 | 1997-10-30 | Shionogi & Co., Ltd. | Sertindole preparation and process for the production thereof |
| JPH1036290A (en) * | 1997-04-25 | 1998-02-10 | Takeda Chem Ind Ltd | Stabilizer for medical solid composition and stabilization thereof |
-
2000
- 2000-08-18 JP JP2000248258A patent/JP2001151671A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH02174931A (en) * | 1988-09-27 | 1990-07-06 | Takeda Chem Ind Ltd | Nucleate granule and its preparation |
| WO1997039752A1 (en) * | 1996-04-24 | 1997-10-30 | Shionogi & Co., Ltd. | Sertindole preparation and process for the production thereof |
| JPH1036290A (en) * | 1997-04-25 | 1998-02-10 | Takeda Chem Ind Ltd | Stabilizer for medical solid composition and stabilization thereof |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6699584B2 (en) * | 2000-12-14 | 2004-03-02 | Otsuka Chemical Co., Ltd. | Nitric acid-based salt granule and aggregate thereof |
| JP2014080424A (en) * | 2002-12-10 | 2014-05-08 | Cps Orocel Llc | Method of preparing biologically active formulations |
| WO2021002411A1 (en) * | 2019-07-04 | 2021-01-07 | 沢井製薬株式会社 | Method for manufacturing orally disintegrating tablet, and orally disintegrating tablet |
| JP2021011443A (en) * | 2019-07-04 | 2021-02-04 | 沢井製薬株式会社 | Method for producing orally disintegrating tablets and orally disintegrating tablets |
| JP2021181434A (en) * | 2020-05-14 | 2021-11-25 | 沢井製薬株式会社 | Water-insoluble polymer-coated granules, formulations containing them and methods for manufacturing them |
| JP7761403B2 (en) | 2020-05-14 | 2025-10-28 | 沢井製薬株式会社 | Water-insoluble polymer-coated granules, preparations containing the same, orally disintegrating tablets, and methods for producing the same |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6264989B1 (en) | Spherical single-substance particles, medicines and foodstuffs containing the particles, and method of production thereof | |
| KR100252188B1 (en) | Stabilized Sustained Release Substrates with Coatings Derived from Water Dispersible Hydrophobic Polymers | |
| JP3707831B2 (en) | Duloxetine enteric pellet | |
| US6149943A (en) | Microcrystalline cellulose particles having active core | |
| EP0593552B1 (en) | Process for preparing drug substances in beadlet form | |
| JP3184912B2 (en) | Preparation method of fine granules suitable for suspension in liquid | |
| JP3778948B2 (en) | Controlled release tablets containing water soluble drugs | |
| AU623177B2 (en) | Granular pharmaceutical formulations | |
| US4900557A (en) | Pellet formulation | |
| JP2001511156A (en) | Fenofibrate pharmaceutical composition with high bioavailability and method for preparing the same | |
| JP3349535B2 (en) | Method for producing spherical granules | |
| JPH09194347A (en) | Production of film-coated particle | |
| Ibrahim | Formulation and evaluation of mefenamic acid sustained release matrix pellets | |
| JPH0776517A (en) | Composition for medicine | |
| JP3130058B2 (en) | Masked granules | |
| JP2813809B2 (en) | Nucleated granule preparation and production method thereof | |
| JP3471977B2 (en) | Enteric preparations coated with solvent-free enteric coatings using liquid plasticizers | |
| JP2001151671A (en) | Particle formulation with protrusion | |
| JP2004067670A (en) | Single substance spherical granules, foods, medicines using them and methods for producing them | |
| US5492700A (en) | Process and composition for the development of controlled release gemfibrozil dosage form | |
| JPH01313431A (en) | Diltiazem microbeads, their preparation and sustained release pharmaceutical compositions | |
| JP4754485B2 (en) | Coprecipitation active substance-containing particles | |
| JP2915653B2 (en) | Masked granules | |
| JP2888581B2 (en) | Method for producing solid pharmaceutical preparation | |
| JPH06157313A (en) | Sustained-release preparation of nicardipine and its production |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20070621 |
|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20080126 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20100708 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100720 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100908 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20101005 |